Intellia Therapeutics (NTLA) Osake Kurssi
Intellia Therapeutics Kurssi
Liikevaihto on kasvanut 27,3 % vuodessa viimeisten 10 vuoden aikana 67,67 M USD:een. Intellia Therapeuticsn nettomarginaali on nyt −609,9 %, noussut −785,8 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 20,50 USD, eli yli nykyhintaa 84,7 %. 25 analyytikosta 14 suosittaa ostoa — kokonaiskonsensus on Osta.
Intellia Therapeutics osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Intellia Therapeutics liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Intellia Therapeutics -osakkeesta
Intellia Therapeutics Inc. is a leading biotechnology company specializing in the development of potentially curative medicines based on CRISPR/Cas9 gene editing technology. The company's business model revolves around using this innovative gene editing platform to develop and commercialize novel therapies for a wide range of genetic diseases. Intellia Therapeutics aims to leverage its expertise in genome editing to provide transformative treatments that address patients' unmet medical needs. By harnessing the power of CRISPR/Cas9, Intellia Therapeutics aims to revolutionize the biotechnology industry and make significant advancements in precision medicine.
Intellia Therapeutics Inc is primarily active in the biotechnology industry.
The main competitors of Intellia Therapeutics Inc in the market include CRISPR Therapeutics AG, Editas Medicine Inc, and Sangamo Therapeutics Inc.
Intellia Therapeutics Inc is a biotechnology company based in Cambridge, Massachusetts. Founded in 2014, Intellia is focused on developing CRISPR/Cas9 genome editing technology for therapeutic applications. The company aims to revolutionize medicine by harnessing the power of CRISPR to eradicate genetic diseases, create more effective and precise treatments, and improve patient outcomes. Intellia has pioneered several groundbreaking research initiatives and strategic collaborations, including partnerships with leading pharmaceutical companies. With a strong commitment to innovation and scientific excellence, Intellia Therapeutics Inc continues to make significant strides in advancing the field of gene editing and unlocking potential cures for debilitating genetic disorders.
Intellia Therapeutics Inc has achieved several significant milestones. Notably, the company successfully entered into a collaboration with Novartis to develop and commercialize CAR-T cell therapies utilizing its CRISPR/Cas9 technology. Additionally, Intellia Therapeutics became the first company to demonstrate in vivo editing using CRISPR/Cas9 in a non-human primate model. Furthermore, the company received FDA clearance for its Investigational New Drug (IND) application for the treatment of transthyretin amyloidosis, which marked a crucial step in developing potential therapies for this rare disease. Intellia Therapeutics continues to make progress in leveraging its innovative gene editing platform to pave the way for novel therapeutic interventions.
Intellia Therapeutics Inc primarily operates in the United States.
Intellia Therapeutics Inc is a leading biotechnology company that focuses on developing CRISPR/Cas9 genome editing technology. The company's corporate philosophy revolves around innovation, collaboration, and scientific excellence. Intellia Therapeutics is committed to revolutionizing medicine by utilizing CRISPR/Cas9 to potentially treat various genetic diseases. With a mission to develop curative therapeutics, Intellia Therapeutics aims to transform the lives of patients and their families. The company values integrity, diversity, and dedication to science-driven advancements. Through its cutting-edge research and passionate team, Intellia Therapeutics is committed to delivering groundbreaking solutions and making a lasting impact in the field of gene editing.
Analyytikot asettavat tällä hetkellä Intellia Therapeutics-osakkeelle keskimääräisen tavoitehinnan 23,40 USD (mediaani: 20,50 USD), mikä merkitsee +110,8 % viimeisimpään hintaan verrattuna. Konsensus perustuu 25 analyytikkoarvioon.
25 analyytikkoa arvioi tällä hetkellä Intellia Therapeutics-osaketta: 14 suosittaa ostoa, 7 pitoa ja 4 myyntiä. Vuodelle 2026 analyytikot odottavat Intellia Therapeutics-yhtiöltä 50,26 M USD liikevaihtoa ja −3,20 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Intellia Therapeutics-osake noteerataan hintaan 9,95 EUR (11,10 USD).
Intellia Therapeutics-osake (NTLA) on listattuna 7 pörssissä, muun muassa: NASDAQ (NTLA), London (0JBU.L), SIX (Zürich) (38I.SW), Frankfurt (38I.F), München (38I.MU), Düsseldorf (38I.DU).
Intellia Therapeutics Inc is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapies for genetic diseases. The company utilizes CRISPR/Cas9 gene editing technology to make targeted changes in the human genome and potentially develop life-changing therapies. Intellia is currently focusing on the treatment of liver diseases such as hereditary transthyretin amyloidosis (ATTR) and hemophilia, which is based on a malfunction of the blood clotting system. The company is also dedicated to developing therapies for cancer and rare genetic diseases. Intellia's main products are genetic therapies that aim to remove or repair disease-causing mutations in patients' genomes. These therapies utilize CRISPR/Cas9 gene editing technology to cut and efficiently edit DNA. The company has also formed partnerships with other biotechnology and pharmaceutical companies to apply this technology to other areas of medicine and research. Intellia has a pipeline of therapies in various stages of development. The company collaborates closely with academics and industry experts to explore and expand the technology and the benefits of clinical medical studies and more precise diagnostic procedures. Intellia's business strategy is to bring significant therapeutic innovations to market by leveraging its expertise in CRISPR/Cas9 technology. The company has a strong financial position that allows it to invest in the development of innovative therapies and technologies. It has also formed strategic partnerships with companies such as Regeneron Pharmaceuticals and Novartis to accelerate research and development. Intellia believes that its technology has the potential to revolutionize the treatment of diseases and create immense opportunities for scientists, patients, and investors over time. The company is committed to utilizing CRISPR/Cas9 technology to develop groundbreaking therapies that improve patients' lives and advance medical research.
odotettu liikevaihto Intellia Therapeutics on 50,26 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Intellia Therapeutics on −346,66 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Intellia Therapeutics:n hinta-voitto-suhde (P/E) on tällä hetkellä −3,47. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Intellia Therapeutics-osakkeen arvostusta.
Intellia Therapeutics:n hinta-myynti-suhde (P/S) on tällä hetkellä 23,93. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Intellia Therapeutics-osakkeen arvostuskennuslukuna.
Intellia Therapeutics:n Eulpool-laatuscore on 5/10.
Intellia Therapeutics:n ISIN on US45826J1051. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Intellia Therapeutics:n WKN on A2AG6H. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Intellia Therapeutics:n ticker on NTLA. Tämä pörssinoteeraus käytetään Intellia Therapeutics-osakkeiden kauppaan pörssissä.
Intellia Therapeutics osake
Intellia Therapeutics vertaisryhmä
Intellia Therapeutics Ticker
Intellia Therapeutics FIGI
Kaikki tunnusluvut ja syvällinen analyysi Intellia Therapeutics:sta
Meidän osakeanalyysimme Intellia Therapeutics-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Intellia Therapeutics:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: